AzTrials
AzTrials

Breast NeoplasmsNCT03528473

Adapted Physical Activity (APA) in a Breast Cancer Population.

A study testing Exercise in people with Breast Neoplasms and Exercise, run by University Of Perugia at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of this study is to investigate the effect of a 6-months program of Adapted Physical Activity (APA) on lifestyle, physical activity levels, insulin resistance and adipokines, oxidative stress, microcirculatory haemodynamics and serum levels of specific circulating miRNA in post-menopausal, physically inactive… Read more about this study

Who is it for?
Ages 18 to 80 years, women only
Conditions the study is for
Breast Neoplasms, Exercise, Exercise Therapy
What is being tested?
Exercise
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteItaly
Study dates
1 Jan 2019to 31 Dec 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • breast cancer patients in oncological follow-up
  • post-menopausal age
  • physically inactivity (light to moderate or vigorous leisure-time physical activity less than 10 minutes a day, US National Health Interview Survey)
  • assuming or not hormone therapy
  • after 3 months - 3 years from adjuvant post-surgical treatment (radiotherapy and/or chemotherapy)

Who cannot join

  • Permanent
  • Patients older than 80 years
  • Inability to carry on physical activity
  • Metastatic neoplasia or unknown stage and/or histology
  • Concomitant neoplasia
  • Patients on corticosteroid treatment
Show all 17Show fewer
  • Known heart disease (heart failure NYHA II (New York Heart Association II) or superior, angina pectoris or positive exercise stress test, treatment-related cardiotoxicity)
  • Currently on a weight loss plan or on moderate physical activity before the start of the project (no more than three sessions a week)
  • Severe cachexia (loss of more than of 35% premorbid weight or weight loss more than 10% in the last 6 months).
  • Morbidly obesity (BMI >40 kg/m2),
  • Immunodepression (absolute neutrophils count < 500/mmc)
  • Temporary
  • Uncontrolled pain or new onset bone pain until further diagnostic study
  • Severe anemia (haemoglobin below 8 g/dL) or platelet count lower than <50000/μL
  • Fever (temperature above 38ºC) or acute infections
  • Severe nausea and vomiting within previous 24-36 h
  • Uncontrolled blood pressure (systolic blood pressure > 160 mm Hg and/or diastolic blood pressure >99 mm Hg)

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • University of Perugia

    Perugia, 06132

Other trials in Italy

About this study

Official title: Adapted Physical Activity (APA), Insulin Resistance, Oxidative Stress and Microcirculatory Haemodynamics in Breast Cancer Patients.

The aim of this study is to investigate the effect of a 6-months program of Adapted Physical Activity (APA) on lifestyle, physical activity levels, insulin resistance and adipokines, oxidative stress, microcirculatory haemodynamics and serum levels of specific circulating miRNA in post-menopausal, physically inactive breast cancer patients in oncologic follow-up with or without hormone therapy that had completed adjuvant treatment (radiotherapy and/or chemotherapy) .

Furthermore, the study will determine the impact of APA on functional capabilities, on self-reported physical activity, quality of life and psychic health.

Read the detailed description

This is a randomized controlled double-group assignment study with intermedial switch-over including post-menopausal, physically inactive breast cancer patients in oncological follow-up with or without hormone therapy, that had completed adjuvant post-surgical treatment (radiotherapy and/or chemotherapy) from at least 3 months and from not more than 3 years.

Patients in hormonal therapy and patient not in hormonal therapy will be assigned in two different groups, each one of 50 patients. In each groups, patients will be randomized divided in a control group (25 pt) and in a 6 months-physical training group (25 pt). After 6-months patient in control group will be switched in the physical training group.

The duration of the study is 2 year. Clinical evaluation of the patients will be made: at the enrollment, after 6, 12, and 24 months.

Physical activity will be adapted according to arm and shoulder morbidity, after fracture risk assessment. Exercise will be concentrated solely on leg muscles (pedalling on a cycle or bed ergometer) in individuals with limitations in the range of motion of the arms (eg, due to breast, axillary, or thoracic surgery). In patients experiencing ataxia, dizziness, or peripheral neuropathy, walking outdoors and mostly cycle-ergometry training will be preferred to other activities that also involve large muscle groups but require additional balance and coordination (eg, treadmill walking, outdoor cycling).

Exercises will be performed at the Unipolar Spinal Unit of "S. Maria della Misericordia" Hospital, Perugia.

The aim of the study is to confirm the positive effect of APA on metabolic stress, body mass composition, functional capacity, serum levels of specific circulating miRNA and quality of life in breast cancer patients in oncological follow-up.

Currently, only few data are available about the relationship between physical activity and microcirculatory hemodynamics that, together with oxidative stress, could be involved in genesis and progression of breast cancer.

Being tested
Exercise
Medical subject headings
Breast Neoplasms, Motor Activity, Insulin Resistance, Atherosclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ExerciseOther

    The exercise intervention consists of 60 minutes sessions, divided into 40 minutes of aerobic exercise and 20 minutes of circuit training for muscular strength and flexibility exercises.

    Aerobic exercise is performed using treadmill, exercise bikes, syncro and arm-ergometers, gradually increasing the exercise intensity, after a 10 minutes period of warming-up, to 60-80 % of Maximum Heart Rate.

    Resistance training consists of resistance exercises for large muscle groups, performed with body weight-exercises and isotonic machines.

Study groups in NCT03528473
Study groupRoleWhat they receive
ExerciseExperimentalPatients involved in the 6 months-physical training group.
Receives: Other: Exercise
ControlNo interventionPatients in control group carry on their usual follow-up programme.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in physical activity levels

    Self reported physical activity, using IPAQ-SF (International Physical Activity Questionnairev - Short Form) score

    Measured: Evaluation baseline and after 6, 12 and 24 months from enrollment.

  2. Change in BMI

    Reduction of BMI expressed as body mass (kg) / height^2 (m^2)

    Measured: Evaluation baseline and after 6, 12 and 24 months from enrollment.

Secondary outcomes (10)
  1. Change in Post-Occlusive Reactive Hyperemia (PORH)

    Improvement of Area of Hyperemia (AH) at Post-Occlusive Reactive Hyperemia (PORH) on Laser Doppler velocimetry (Periflux System 5000, Perimed), expressed as Perfusion Units (PU).

    Measured: Evaluation baseline and after 6, 12 and 24 months from enrollment.

  2. Carotid intima-media thickness (IMT)

    Improvement of macrovascular structures, that will be explored by carotid intima-media thickness (IMT) (two-dimensional B-mode ultrasonography), measured in mm.

    Measured: Evaluation baseline and after 6, 12 and 24 months from enrollment.

  3. Arterial stiffness

    Reduction of arterial stiffness, that will be evaluated by radial applanation tonometry (SphygmoCor) and general transfer function assessing PWV (measure in m/s).

    Measured: Evaluation baseline and after 6, 12 and 24 months from enrollment.

  4. Hemorheological profile

    Improvement of Hemorheological profile, that will be studied with Serum, Plasma, and Blood Viscosity (Haake rotational viscometer), measured as mPas.

    Measured: Evaluation baseline and after 6, 12 and 24 months from enrollment.

  5. Serum adiponectin

    Improvement of serum adiponectin, measured by ELISA-method (ng/ml). Blood samples will be collected in the morning between 7:00 and 9:00 am, after overnight fasting.

    Measured: Evaluation baseline and after 6, 12 and 24 months from enrollment.

  6. Serum IGF-1

    Improvement of serum IGF-1, measured by ELISA-method (ng/ml). Blood samples will be collected in the morning between 7:00 and 9:00 am, after overnight fasting.

    Measured: Evaluation baseline and after 6, 12 and 24 months from enrollment.

  7. VFA (Visceral Fat Area)

    Improvement of Ultrasound assesment of visceral fat area (VFA, by MyLab 50 Ultrasonography, Esaote), measured by Hirooka formula (cm^2)

    Measured: Evaluation baseline and after 6, 12 and 24 months from enrollment.

  8. HOMA-IR index

    Homeostatic model assessment (HOMA) for insulin resistance (IR) is a method for assessing β-cell function and insuline resistance from basal (fasting) glucose and insulin or C-peptide concentrations. HOMA-IR can be calculated with a simple mathematical approximation as HOMA-IR = (FPI × FPG)/22.5, where FPI is fasting plasma insulin concentration (mU/l) and FPG is fasting plasma glucose (mmol/l), or as HOMA-IR = (FPI × FPG)/405 if fasting plasma glucose is expressed in mg/dl.

    Values bethween 3 and 5 are considered expression of moderate insuline resistance; values upper 5 are considered expression of severe insuline resistance.

    Improvement of insulin-sensitivity expressed as HOMA-IR index reduction.

    Measured: Evaluation baseline and after 6, 12 and 24 months from enrollment.

  9. Maximal aerobic capacity (VO2max)

    Increase of maximal aerobic capacity after physical training, measured as ml/kg/min.

    Measured: Evaluation baseline and after 6, 12 and 24 months from enrollment.

  10. miRNA

    Variation of serum miR-10b, 15a, 146, 155, 375 e let-7a,b,c concentrations.

    Measured: Evaluation baseline and after 6, 12 and 24 months from enrollment.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 May 2018
  2. Study start1 Jan 2019
  3. Primary completion31 Dec 2022 (estimated)
  4. Study completion31 Dec 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is a randomized, controlled, double-group assignment, open label study with intermediate crossover
Masking
None (open label)
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03528473
Sponsor's protocol ID
APA-PG1
Status last verified
Sep 2021
First submitted
22 Mar 2018
Last updated
5 Oct 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Adraskela K, Veisaki E, Koutsilieris M, Philippou A. Physical Exercise Positively Influences Breast Cancer Evolution. Clin Breast Cancer. 2017 Oct;17(6):408-417. doi: 10.1016/j.clbc.2017.05.003. Epub 2017 May 19.

    PubMed 28606800
  • Foucaut AM, Berthouze-Aranda SE, Touillaud M, Kempf-Lepine AS, Baudinet C, Meyrand R, Carretier J, Bachmann P, Fervers B. Reduction of health risk factors through an adapted physical activity program in patients with breast cancer. Support Care Cancer. 2014 Apr;22(4):1097-104. doi: 10.1007/s00520-013-2065-3. Epub 2013 Dec 3.

    PubMed 24292096
  • Franses JW, Edelman ER. The evolution of endothelial regulatory paradigms in cancer biology and vascular repair. Cancer Res. 2011 Dec 15;71(24):7339-44. doi: 10.1158/0008-5472.CAN-11-1718. Epub 2011 Dec 5.

    PubMed 22144472
  • Ye J, Jia J, Dong S, Zhang C, Yu S, Li L, Mao C, Wang D, Chen J, Yuan G. Circulating adiponectin levels and the risk of breast cancer: a meta-analysis. Eur J Cancer Prev. 2014 May;23(3):158-65. doi: 10.1097/CEJ.0b013e328364f293.

    PubMed 23929213
  • Tesarova P, Kalousova M, Zima T, Suchanek M, Malikova I, Kvasnicka J, Duskova D, Tesar V, Vachek J, Krupickova-Kasalova Z, Malik J. Endotelial activation and flow-mediated vasodilation in young patients with breast cancer. Neoplasma. 2013;60(6):690-7. doi: 10.4149/neo_2013_088.

    PubMed 23906304

Questions about this trial

What is this clinical trial studying?

A study testing Exercise in people with Breast Neoplasms and Exercise, run by University Of Perugia at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 5 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in physical activity levels (time frame: Evaluation baseline and after 6, 12 and 24 months from enrollment.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03528473, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in